Ion Beam Applications, S.A. announced revenue results for the year to date ended September 30, 2016. The year to date group revenues of EUR 225.3 million, up 19.3% year-on-year, driven by excellent revenue recognition of Proton Therapy projects (positive 43.7% versus last year), more than offsetting declining Dosimetry (negative 12.8% versus last year) and flat revenues of Other Accelerators division.

Revenues for the full-year expected to be around 20% higher than in 2015, reflecting strong PT growth and more than offsetting Dosimetry weakness; operating margin expected to be around 10%, slightly below previous expectations of 11% due to the weak Dosimetry market; the company expects operating margins to rise to 13-15% by 2018.